1175 related articles for article (PubMed ID: 22177371)
21. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
22. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
23. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
Cope S; Capkun-Niggli G; Gale R; Lassen C; Owen R; Ouwens MJ; Bergman G; Jansen JP
Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
[TBL] [Abstract][Full Text] [Related]
25. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T
Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
[TBL] [Abstract][Full Text] [Related]
29. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
Chapman KR; Rennard SI; Dogra A; Owen R; Lassen C; Kramer B;
Chest; 2011 Jul; 140(1):68-75. PubMed ID: 21349928
[TBL] [Abstract][Full Text] [Related]
31. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
[TBL] [Abstract][Full Text] [Related]
32. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
33. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
[TBL] [Abstract][Full Text] [Related]
34. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
[TBL] [Abstract][Full Text] [Related]
35. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
Pearlman DS; Greos L; LaForce C; Orevillo CJ; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
[TBL] [Abstract][Full Text] [Related]
36. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
[TBL] [Abstract][Full Text] [Related]
37. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
Korn S; Kerwin E; Atis S; Amos C; Owen R; Lassen C;
Respir Med; 2011 May; 105(5):719-26. PubMed ID: 21367594
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
[TBL] [Abstract][Full Text] [Related]
39. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
Hoshino M; Ohtawa J; Akitsu K
Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
